Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences
Authors
Keywords
-
Journal
Targeted Oncology
Volume 13, Issue 2, Pages 125-140
Publisher
Springer Nature
Online
2018-01-04
DOI
10.1007/s11523-017-0547-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Systematic Review of Immune Checkpoint Inhibition in Urological Cancers
- (2017) Maud Rijnders et al. EUROPEAN UROLOGY
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation
- (2016) Henrique Lemos et al. CANCER RESEARCH
- Regulatory T cells in cancer immunotherapy
- (2016) Atsushi Tanaka et al. CELL RESEARCH
- Reversing T-cell Dysfunction and Exhaustion in Cancer
- (2016) H. M. Zarour CLINICAL CANCER RESEARCH
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer.
- (2016) Nathan Bahary et al. JOURNAL OF CLINICAL ONCOLOGY
- Tolerogenic Phenotype of IFN-γ–Induced IDO+Dendritic Cells Is Maintained via an Autocrine IDO–Kynurenine/AhR–IDO Loop
- (2016) Qingsheng Li et al. JOURNAL OF IMMUNOLOGY
- An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone
- (2016) Soo Jeong Nam et al. LEUKEMIA & LYMPHOMA
- Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing
- (2016) Qi Chen et al. NATURE IMMUNOLOGY
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relationship between indoleamine 2,3-dioxygenase activity and lymphatic invasion propensity of colorectal carcinoma
- (2016) Atilla Engin et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
- (2016) Caroline Jochems et al. Oncotarget
- A phase I study of indoximod in patients with advanced malignancies
- (2016) Hatem H. Soliman et al. Oncotarget
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients
- (2015) Yunlong Jia et al. INTERNATIONAL JOURNAL OF CANCER
- Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice
- (2015) Nobuhiko Nakamura et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
- (2015) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia
- (2015) Ryoko Mabuchi et al. LEUKEMIA & LYMPHOMA
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- The prognostic significance of indoleamine-2,3-dioxygenase and the receptors for transforming growth factor β and interferon γ in metastatic lymph nodes in malignant melanoma
- (2015) Maciej J. Pelak et al. POLISH JOURNAL OF PATHOLOGY
- The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity
- (2015) Buvana Ravishankar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity
- (2015) Olivier Demaria et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
- (2015) Bin Shang et al. Scientific Reports
- Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
- (2015) Rikke B. Holmgaard et al. Cell Reports
- Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival
- (2015) Debbie M Ferns et al. OncoImmunology
- The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment
- (2015) M. D. Sharma et al. Science Advances
- Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers
- (2015) Tara C Gangadhar et al. Journal for ImmunoTherapy of Cancer
- Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia
- (2015) Valentina Folgiero et al. Oncotarget
- A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
- (2015) Hatem H. Soliman et al. Oncotarget
- FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients
- (2014) Marisa Ryan et al. AMERICAN JOURNAL OF OTOLARYNGOLOGY
- Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
- (2014) I. Chevolet et al. BRITISH JOURNAL OF DERMATOLOGY
- Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy.
- (2014) Mario R. Mautino et al. CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
- (2014) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
- (2014) Liufu Deng et al. IMMUNITY
- Indoleamine 2,3-Dioxygenase 1 (IDO1) Is Up-Regulated in Thyroid Carcinoma and Drives the Development of an Immunosuppressant Tumor Microenvironment
- (2014) Sonia Moretti et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cutting Edge: Autocrine TGF- Sustains Default Tolerogenesis by IDO-Competent Dendritic Cells
- (2014) M. L. Belladonna et al. JOURNAL OF IMMUNOLOGY
- Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
- (2014) Rituparna Das et al. JOURNAL OF IMMUNOLOGY
- Activation of the STING Adaptor Attenuates Experimental Autoimmune Encephalitis
- (2014) H. Lemos et al. JOURNAL OF IMMUNOLOGY
- The role of IDO in brain tumor immunotherapy
- (2014) Lijie Zhai et al. JOURNAL OF NEURO-ONCOLOGY
- Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics
- (2014) Kenji Fukuno et al. LEUKEMIA & LYMPHOMA
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- Immunological Relevance of the Coevolution of IDO1 and AHR
- (2014) Merja Jaronen et al. Frontiers in Immunology
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Aryl hydrocarbon receptor signaling regulates NF-κB RelB activation during dendritic-cell differentiation
- (2013) Christoph F A Vogel et al. IMMUNOLOGY AND CELL BIOLOGY
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cutting Edge: DNA Sensing via the STING Adaptor in Myeloid Dendritic Cells Induces Potent Tolerogenic Responses
- (2013) L. Huang et al. JOURNAL OF IMMUNOLOGY
- Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration
- (2013) Xiao-Qian Liu et al. LEUKEMIA & LYMPHOMA
- GCN2-Dependent Metabolic Stress Is Essential for Endotoxemic Cytokine Induction and Pathology
- (2013) H. Liu et al. MOLECULAR AND CELLULAR BIOLOGY
- Expression of Indoleamine 2,3-Dioxygenase and Correlation With Pathological Malignancy in Gliomas
- (2013) Kentaro Mitsuka et al. NEUROSURGERY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
- (2013) Ben C. Creelan et al. OncoImmunology
- IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival
- (2012) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma
- (2012) Renske A. de Jong et al. GYNECOLOGIC ONCOLOGY
- Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma
- (2012) Jin Ye et al. VIRCHOWS ARCHIV
- Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer
- (2011) L Ferdinande et al. BRITISH JOURNAL OF CANCER
- Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival
- (2011) Jonathan R. Brody et al. CELL CYCLE
- Involvement of Indoleamine 2,3-Dioxygenase in Impairing Tumor-Infiltrating CD8+T-Cell Functions in Esophageal Squamous Cell Carcinoma
- (2011) Ge Zhang et al. Clinical & Developmental Immunology
- Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients
- (2011) Reinhart Speeckaert et al. EUROPEAN JOURNAL OF CANCER
- Expression of indoleamine 2,3-dioxygenase predicts shorter survival in patients with vulvar squamous cell carcinoma (vSCC) not influencing on the recruitment of FOXP3-expressing regulatory T cells in cancer nests
- (2011) Jacek J. Sznurkowski et al. GYNECOLOGIC ONCOLOGY
- High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma
- (2011) Jocelyne Jacquemier et al. INTERNATIONAL JOURNAL OF CANCER
- Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
- (2011) Maria T Pallotta et al. NATURE IMMUNOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas
- (2011) Klaus Laimer et al. ORAL ONCOLOGY
- The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
- (2011) Christiane A. Opitz et al. PLoS One
- Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP
- (2010) Soranobu Ninomiya et al. ANNALS OF HEMATOLOGY
- Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
- (2010) X. Liu et al. BLOOD
- Inhibitor of Indoleamine-2,3-Dioxygenase 1-Methyl-D-Tryptophan Can Stimulate the Growth of Immunogenic Tumors
- (2010) E. D. Vasil’eva et al. BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE
- Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy
- (2010) Tomoko Inaba et al. GYNECOLOGIC ONCOLOGY
- An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
- (2010) J. D. Mezrich et al. JOURNAL OF IMMUNOLOGY
- Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors
- (2010) H. K. Koblish et al. MOLECULAR CANCER THERAPEUTICS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis
- (2010) F. J. Quintana et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma
- (2009) Hiroshi Urakawa et al. CLINICAL & EXPERIMENTAL METASTASIS
- Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP
- (2009) Takeshi Yoshikawa et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma
- (2009) Tomoko Inaba et al. GYNECOLOGIC ONCOLOGY
- IDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells
- (2009) B. Baban et al. JOURNAL OF IMMUNOLOGY
- The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer
- (2009) Yan-Fang Gao et al. Journal of Translational Medicine
- IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
- (2008) Stefan Löb et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival
- (2008) K. Ino et al. CLINICAL CANCER RESEARCH
- High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome
- (2008) M. E.D. Chamuleau et al. HAEMATOLOGICA
- Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma
- (2008) Ke Pan et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients’ sera by HPLC and is inducible by IFN-γ
- (2008) Selim Corm et al. LEUKEMIA RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started